These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 19525731

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
    Geyer O, Schmidt KG, Pianka P, Neudorfer M, Lazar M.
    Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):149-52. PubMed ID: 10766284
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants.
    Watts P, Satterfield D, Lim MK.
    J AAPOS; 2007 Jun; 11(3):282-3. PubMed ID: 17572343
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
    Costagliola C, Parmeggiani F, Ciancaglini M, D'Oronzo E, Mastropasqua L, Sebastiani A.
    Ophthalmologica; 2003 Jun; 217(1):39-44. PubMed ID: 12566871
    [Abstract] [Full Text] [Related]

  • 30. High incidence of topical allergic reactions to 1% apraclonidine.
    Feibel RM.
    Arch Ophthalmol; 1995 Dec; 113(12):1579-80. PubMed ID: 7487638
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
    Crichton AC.
    Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
    [No Abstract] [Full Text] [Related]

  • 35. The role of alpha-agonists in glaucoma therapy.
    Robin AL.
    Curr Opin Ophthalmol; 1997 Apr; 8(2):42-9. PubMed ID: 10168356
    [Abstract] [Full Text] [Related]

  • 36. More than just an ocular solution.
    Pekdemir M, Yanturali S, Karakus G.
    Emerg Med J; 2005 Oct; 22(10):753-4. PubMed ID: 16189050
    [Abstract] [Full Text] [Related]

  • 37. Prevalence of uveitic secondary glaucoma and success of nonsurgical treatment in adults and children in a tertiary referral center.
    Heinz C, Koch JM, Zurek-Imhoff B, Heiligenhaus A.
    Ocul Immunol Inflamm; 2009 Oct; 17(4):243-8. PubMed ID: 19657977
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.